Acquisition

October 01, 2026 The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Dear Sir/ Madam, Trading Symbol: ZOTA Sub: Intimation of Acquisition of 20,20,000 equity shares of M/s Curexis Ventures Private Limited, Wholly Owned Subsidiary of the Company, by way of subscription to the right issue. Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the captioned subject; we, M/s Zota Health Care Limited (the “Company”), would like to inform you that the Company has acquired 20,20,000 equity shares of M/s Curexis Ventures Private Limited, Wholly Owned Subsidiary (“WOS”) of the Company, by way of subscription to the right issue. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are annexed herewith as Annexure-1. This is for your information and record. Thanking you, Yours faithfully, For Zota Health Care Limited Ashvin Variya (Group Company Secretary & Compliance Officer) Place: Surat Encl.: a/a Registered Office: Zota House, 2/896, Hira Modi Street, Sagrampura, Surat-395002 Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352 Annexure-1 Particulars Details Name of the target entity, details in brief such i. Name of the Target Entity: Curexis Ventures Private as size, turnover etc. Limited ii. Business of the Target Entity: Established as a drug manufacturing, development, and marketing company. WOS is engaged in the business of running retail pharmacy stores under the brand name of “SKIA” offering wide range of Pharmaceutical, Nutraceutical, Cosmetic, Ayurvedic and OTC products. iii. Financial details: As per the audited financial statements for the Financial Year 2025-26, the turnover of WOS was Rs. 1.18 lakhs. At present, the total paid-up share capital is Rs. 101 lakhs. Whether the acquisition would fall within No, the acquisition does not fall within the ambit of related related party transaction(s) and whether the party transactions. The promoter/ promoter group/ group promoter/ promoter group/ group companies companies do not have any interest in WOS and the said have any interest in the entity being acquired? transaction is done at arm’s length basis. If yes, nature of interest and details thereof and whether the same is done at “arm’s length” Industry to which the entity being acquired Pharmaceutical belongs Objects and effects of acquisition (including The Company is subscribing equity shares on right basis but not limited to, disclosure of reasons for offered by the WOS, wherein the WOS would utilise the acquisition of target entity, if its business is issue proceeds for repayment of outstanding Unsecured outside the main line of business of the listed loan availed from the Company. The said investment would entity); result into reduction in Group’s total outstanding debt on a consolidated basis and improves overall net worth of the Group. Post to this acquisition, M/s Curexis Ventures Private Limited continues to remain as the WOS of the Company. Brief details of any governmental or N.A. regulatory approvals required for the acquisition Indicative time period for completion of the On October 01, 2026, the Company has acquired the said acquisition 20,20,000 equity shares of WOS by subscription to the right issue. Nature of consideration - whether cash Cash consideration by way of acquisition of Equity Shares. consideration or share swap and details of the same; Cost of acquisition or the price at which the Cost of acquisition for subscription of 20,20,000 Equity shares are acquired Shares offered on right basis is Rs. 20.00/- per equity share (including premium of Rs. 10.00/- per equity share) aggregating to Rs. 4,04,00,000.00/-. Percentage of shareholding / control acquired The Company has acquired 20,20,000 equity shares of and / or number of shares acquired WOS. Post to this acquisition, M/s Curexis Ventures Private Limited continues to remain as the WOS of the Company. Brief background about the entity acquired in M/s Curexis Ventures Private Limited was incorporated on terms of products/line of business acquired, February 25, 2025, domiciled in India; engaged in drug date of incorporation, history of last 3 years manufacturing, development, and marketing company. turnover, country in which the acquired entity WOS is engaged in the business of running retail pharmacy has presence and any other significant stores under the brand name of “SKIA” offering wide range information (in brief) of Pharmaceutical, Nutraceutical, Cosmetic, Ayurvedic and OTC products. During last three financial years, the details of turnover of WOS were as follows: FY 2025-26 Rs. 1.18 Lakhs FY 2024-25 Rs. N.A. FY 2023-24 Rs. N.A.